Cargando…
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma
BACKGROUND: We have previously reported that the sigma-2 receptor is highly expressed in pancreas cancer. Furthermore, we have demonstrated that sigma-2 receptor specific ligands induce apoptosis in a dose-dependent fashion. Here, we examined whether sigma-2 receptor ligands potentiate conventional...
Autores principales: | Kashiwagi, Hiroyuki, McDunn, Jonathan E, Simon, Peter O, Goedegebuure, Peter S, Vangveravong, Suwanna, Chang, Katherine, Hotchkiss, Richard S, Mach, Robert H, Hawkins, William G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669042/ https://www.ncbi.nlm.nih.gov/pubmed/19323815 http://dx.doi.org/10.1186/1479-5876-7-24 |
Ejemplares similares
-
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy
por: Kashiwagi, Hiroyuki, et al.
Publicado: (2007) -
Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer
por: Hornick, John R, et al.
Publicado: (2012) -
Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer
por: Zeng, C, et al.
Publicado: (2013) -
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine
por: Hornick, John R, et al.
Publicado: (2010) -
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer
por: Hashim, Yassar M., et al.
Publicado: (2017)